Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMD 1201081 plus cetuximab versus cetuximab alone in recurrent or metastatic head and neck squamous cell carcinoma
NL-OMON36270Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing EMD 1201081 + cetuximab with cetuximab alone (2 arms). Primary endpoint: Progression-free survival. Started Apr 2011; status: active, not recruiting.
02
Drugs
IMO-2055cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON36270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36270.